CN1882587B - 三环化合物作为甘氨酸转运抑制剂的用途 - Google Patents

三环化合物作为甘氨酸转运抑制剂的用途 Download PDF

Info

Publication number
CN1882587B
CN1882587B CN2004800335688A CN200480033568A CN1882587B CN 1882587 B CN1882587 B CN 1882587B CN 2004800335688 A CN2004800335688 A CN 2004800335688A CN 200480033568 A CN200480033568 A CN 200480033568A CN 1882587 B CN1882587 B CN 1882587B
Authority
CN
China
Prior art keywords
compound
azabicyclo
trifluoromethyl
group
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800335688A
Other languages
English (en)
Chinese (zh)
Other versions
CN1882587A (zh
Inventor
G·达加赞利
G·埃斯滕内-布托
P·马加特
B·马拉布特
P·罗歇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN1882587A publication Critical patent/CN1882587A/zh
Application granted granted Critical
Publication of CN1882587B publication Critical patent/CN1882587B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN2004800335688A 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途 Expired - Fee Related CN1882587B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0312165 2003-10-17
FR0312165A FR2861076B1 (fr) 2003-10-17 2003-10-17 Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
PCT/FR2004/002643 WO2005037783A2 (fr) 2003-10-17 2004-10-15 Composes tricycliques comme inhibiteurs de transport de glycine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2009101638818A Division CN101684118B (zh) 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途

Publications (2)

Publication Number Publication Date
CN1882587A CN1882587A (zh) 2006-12-20
CN1882587B true CN1882587B (zh) 2012-06-27

Family

ID=34385252

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800335688A Expired - Fee Related CN1882587B (zh) 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途
CN2009101638818A Expired - Fee Related CN101684118B (zh) 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009101638818A Expired - Fee Related CN101684118B (zh) 2003-10-17 2004-10-15 三环化合物作为甘氨酸转运抑制剂的用途

Country Status (32)

Country Link
US (3) US7288656B2 (cg-RX-API-DMAC7.html)
EP (1) EP1680421B1 (cg-RX-API-DMAC7.html)
JP (1) JP4853918B2 (cg-RX-API-DMAC7.html)
KR (1) KR101125305B1 (cg-RX-API-DMAC7.html)
CN (2) CN1882587B (cg-RX-API-DMAC7.html)
AT (1) ATE386036T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004281217B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415489A (cg-RX-API-DMAC7.html)
CA (1) CA2542647C (cg-RX-API-DMAC7.html)
CR (1) CR8342A (cg-RX-API-DMAC7.html)
CY (1) CY1108925T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004011806T2 (cg-RX-API-DMAC7.html)
DK (1) DK1680421T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP066511A (cg-RX-API-DMAC7.html)
ES (1) ES2300837T3 (cg-RX-API-DMAC7.html)
FR (1) FR2861076B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20080186T3 (cg-RX-API-DMAC7.html)
IL (1) IL174940A (cg-RX-API-DMAC7.html)
MA (1) MA28099A1 (cg-RX-API-DMAC7.html)
ME (1) ME00111B (cg-RX-API-DMAC7.html)
NO (1) NO335462B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ547163A (cg-RX-API-DMAC7.html)
OA (1) OA13317A (cg-RX-API-DMAC7.html)
PL (1) PL1680421T3 (cg-RX-API-DMAC7.html)
PT (1) PT1680421E (cg-RX-API-DMAC7.html)
RS (2) RS20060314A (cg-RX-API-DMAC7.html)
RU (1) RU2346945C2 (cg-RX-API-DMAC7.html)
SG (1) SG147435A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN06110A1 (cg-RX-API-DMAC7.html)
UA (1) UA81186C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005037783A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603861B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
JP2007530664A (ja) * 2004-03-30 2007-11-01 ペインセプター ファーマ コーポレーション ゲートイオンチャンネルを調節するための組成物及び方法
FR2906251B1 (fr) * 2006-09-22 2008-11-07 Sanofi Aventis Sa Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique
US11817637B2 (en) 2006-11-18 2023-11-14 Rfmicron, Inc. Radio frequency identification (RFID) moisture tag(s) and sensors with extended sensing via capillaries
US9582981B2 (en) 2014-10-08 2017-02-28 Rfmicron, Inc. Radio frequency identification (RFID) moisture tag(s) and sensors with extended sensing via capillaries
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
BRPI0922787A2 (pt) * 2008-12-04 2017-07-11 Sanofi Sa Formas polimórficas de um derivado da azabiciclo-trifluorometil benzamida
JP2012516326A (ja) * 2009-01-28 2012-07-19 アストラゼネカ・アクチエボラーグ ２−アザ−ビシクロ［２．２．１］ヘプタン化合物及びそれらの使用
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
FR2941954B1 (fr) * 2009-02-10 2011-04-08 Sanofi Aventis Derives de n-°(6-aza-bicyclo°3.2.1!oct-1-yl)-aryl-methyl! benzamide, leur preparation et leur application en therapeutique
FR2941953B1 (fr) * 2009-02-10 2011-04-08 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-benzamide, leur preparation et leur application en therapeutique
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
FR2943059A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
RU2011141778A (ru) * 2009-03-16 2013-04-27 Санофи Производные n-[(2-азабицикло[2.1.1]гекс-1-ил)арилметил]гетеробензамида, их получение и их применение в терапии
FR2944284A1 (fr) * 2009-04-14 2010-10-15 Sanofi Aventis Derives de n-°7-aza-bicyclo°2.2.1!hept-1-yl)-aryl-methyl! -benzamide, leur preparation et leur application en therapeutique
US8153653B2 (en) 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) * 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
TR201806764T4 (tr) * 2011-11-29 2018-06-21 Vivozon Inc Yeni benzamid türevi ve bunun kullanımı.
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
KR20160062164A (ko) 2013-10-17 2016-06-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 아미노크로만, 아미노티오크로만 및 아미노-1,2,3,4-테트라하이드로퀴놀린 유도체, 이들을 포함하는 약제학적 조성물, 및 치료에서 이들의 용도
CA2924699A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6906227B2 (ja) * 2017-08-18 2021-07-21 国立大学法人千葉大学 ハロゲン結合ドナー／有機塩基複合型化合物及び酸塩基複合触媒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066662A (en) * 1973-12-14 1978-01-03 Science Union Et Cie., Societe Francaise De Recherche Medicale N-substituted-2-aminomethyl-3-azabicyclo(3,3,0)octane compounds
CA1223873A (en) * 1982-04-14 1987-07-07 Francis D. King Pharmaceutically active compounds
ES2051753T3 (es) * 1986-12-16 1994-07-01 Robins Co Inc A H N-(1-azabiciclo(2.2.2)octo-3-il) benzamidas y tiobenzamidas ansioliticas.
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
EP1058684A1 (en) * 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAULFIELD ET AL.The first potent and selective Inhibitors.......JOURNAL OF MEDICINAL CHEMISTRY44 17.2001,44(17),2679-2682.
CAULFIELD ET AL.The first potent and selective Inhibitors.......JOURNAL OF MEDICINAL CHEMISTRY44 17.2001,44(17),2679-2682. *
GALLARDO M.A.ET AL.Influence of hypo-osmolality on the activity.......J.MEMBRANE BIOL.155.1997,155113-119. *

Also Published As

Publication number Publication date
CA2542647A1 (fr) 2005-04-28
US7619089B2 (en) 2009-11-17
PL1680421T3 (pl) 2008-07-31
CN1882587A (zh) 2006-12-20
PT1680421E (pt) 2008-05-13
FR2861076A1 (fr) 2005-04-22
RU2346945C2 (ru) 2009-02-20
CA2542647C (fr) 2012-07-10
TNSN06110A1 (fr) 2007-11-15
KR20060109432A (ko) 2006-10-20
JP2007508361A (ja) 2007-04-05
ECSP066511A (es) 2006-10-10
WO2005037783A3 (fr) 2005-07-07
AU2004281217B2 (en) 2010-07-22
SG147435A1 (en) 2008-11-28
BRPI0415489A (pt) 2006-12-26
US20060264441A1 (en) 2006-11-23
ZA200603861B (en) 2007-12-27
KR101125305B1 (ko) 2012-03-27
EP1680421B1 (fr) 2008-02-13
CN101684118B (zh) 2013-04-10
US20100022548A1 (en) 2010-01-28
DE602004011806D1 (de) 2008-03-27
NZ547163A (en) 2010-01-29
UA81186C2 (en) 2007-12-10
CY1108925T1 (el) 2014-07-02
FR2861076B1 (fr) 2006-01-06
CR8342A (es) 2006-10-04
DE602004011806T2 (de) 2009-02-05
HK1098465A1 (en) 2007-07-20
HRP20080186T3 (en) 2008-05-31
IL174940A (en) 2010-11-30
OA13317A (fr) 2007-04-13
ES2300837T3 (es) 2008-06-16
ATE386036T1 (de) 2008-03-15
ME00111B (me) 2010-10-10
JP4853918B2 (ja) 2012-01-11
NO20062030L (no) 2006-07-07
MEP12208A (en) 2010-06-10
CN101684118A (zh) 2010-03-31
RU2006116889A (ru) 2007-11-27
IL174940A0 (en) 2006-08-20
US7288656B2 (en) 2007-10-30
AU2004281217A1 (en) 2005-04-28
HK1142887A1 (en) 2010-12-17
MA28099A1 (fr) 2006-08-01
NO335462B1 (no) 2014-12-15
RS51587B (sr) 2011-08-31
US20080070941A1 (en) 2008-03-20
RS20060314A (sr) 2008-08-07
WO2005037783A2 (fr) 2005-04-28
EP1680421A2 (fr) 2006-07-19
DK1680421T3 (da) 2008-06-09
US8513246B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
CN1882587B (zh) 三环化合物作为甘氨酸转运抑制剂的用途
CN100404533C (zh) 奎宁环酰胺衍生物
JP4754494B2 (ja) Ｎ−［フェニル（アルキルピペリジン−２−イル）メチル］ベンズアミド誘導体、この調製方法およびこの治療法における使用
CN100430394C (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
CN101903342B (zh) 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途
JP2000063276A (ja) ５ＨＴ１Ａリガンドとしてのピロロ［１，２―ａ］ピラジン誘導体
TW200538112A (en) Novel compounds
US20090258899A1 (en) Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof
HK1098465B (en) Use of tricyclic compounds as glycine transport inhibitors
HK1142887B (en) Use of tricyclic compounds as glycine transport inhibitors
MXPA06004270A (en) Derivatives of n-heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics
KR20110132565A (ko) Ｎ-〔（２-아자-비시클로〔２.１.１〕헥스-１-일）-아릴-메틸〕-헤테로벤즈아미드의 유도체, 그의 제조 방법 및 그의 치료 용도
US20120071536A1 (en) N-[(2-azabicyclo[2.1.1]hex-1-yl)-aryl-methyl]-benzamide derivatives, preparation thereof, and therapeutic use thereof
FR2944283A1 (fr) Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
FR2943056A1 (fr) Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098465

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098465

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120627

Termination date: 20171015

CF01 Termination of patent right due to non-payment of annual fee